文献速递病毒性肝炎

抗-HBs免疫复合物水平:核苷(酸)类似物停药后HBeAg阴性慢性乙肝肝炎发作的新标志物

Anti-HBs Immune Complex Levels: A Novel Marker of Hepatitis Flare Following Nucleos(t)ide Analog Withdrawal in HBeAg-negative Chronic Hepatitis B.
PubMed 文献 · J Infect Dis · 2026-01-01

BACKGROUND AND AIMS: Humoral immunity is thought to play a key role in the immunopathogenesis of chronic hepatitis B (CHB). Peaks in anti-HBs immune complexes (HBsAg-ICs) have been associated with subsequent HBsAg seroclearance.…

要点

  • 治疗结束时HBsAg-IC≥40 IU/mL与较低的肝炎发作风险相关。
  • 肝炎发作期间HBsAg-IC水平动态升高,随ALT峰值达峰。
  • 有益发作(HBsAg下降≥1 log₁₀)者停药后HBsAg-IC峰值更高。

核心结论

  • 血清HBsAg-IC在慢性乙肝患者中可检测到,治疗结束时低水平与停药后肝炎发作风险相关。
  • 研究结果支持体液免疫在慢性乙肝免疫发病机制中的作用。

研究设计与样本

  • 多中心前瞻性队列中嵌套病例对照分析,共38例非肝硬化HBeAg阴性慢性乙肝停药患者。
  • 病例组24例发生肝炎发作(ALT>5倍正常上限),对照组14例未发作。

主要发现

  • 治疗结束时97%参与者可检测到血清HBsAg-IC。
  • 替诺福韦治疗者治疗结束时HBsAg-IC水平低于其他核苷(酸)类似物治疗者。
  • 纵向分析显示肝炎发作期间HBsAg-IC水平动态升高,随ALT峰值达峰。
  • 有益发作(HBsAg下降≥1 log₁₀)者停药后HBsAg-IC峰值高于非有益发作组。

临床怎么用

  • 治疗结束时检测HBsAg-IC水平可能有助于评估HBeAg阴性慢性乙肝患者停药后肝炎发作风险。
  • 低HBsAg-IC水平(<40 IU/mL)或提示停药后肝炎发作风险较高,需加强监测。

局限性

  • 样本量较小(n=38),为嵌套病例对照分析,结果需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Humoral immunity is thought to play a key role in the immunopathogenesis of chronic hepatitis B (CHB). Peaks in anti-HBs immune complexes (HBsAg-ICs) have been associated with subsequent HBsAg seroclearance. Discontinuation of nucleos(t)ide analog (NA) therapy can promote HBsAg seroclearance but also carries a risk of hepatitis flare. We evaluated the relationship between serum HBsAg-IC levels and hepatitis flare following NA cessation in HBeAg-negative CHB. METHODS: In a multicentre prospective cohort of noncirrhotic HBeAg-negative CHB patients undergoing NA discontinuation, we conducted a nested case-control analysis (n = 38). Stored serum samples were tested for HBsAg-IC at end-of-treatment (EOT) and at serial timepoints off-treatment. Cases (n = 24) experienced a hepatitis flare (ALT >5× upper limit of normal); controls (n = 14) did not. Associations between HBsAg-IC levels and clinical outcomes were analyzed. RESULTS: Serum HBsAg-ICs were detectable in 97% of participants at EOT. High HBsAg-IC levels (≥40 IU/mL) at EOT were less frequent among those who developed hepatitis flare (8%) versus controls (57%, P = .002). Individuals treated with tenofovir (vs other NAs) had lower EOT HBsAg-IC levels. Longitudinal analysis revealed dynamic increases in HBsAg-IC levels during hepatitis flare, peaking with maximal ALT. Participants who experienced beneficial flares (≥1 log₁₀ HBsAg reduction) had higher peak off-treatment HBsAg-IC levels compared to those with nonbeneficial flares. CONCLUSIONS: Serum HBsAg-ICs are detectable in patients with CHB, and low levels at EOT are associated with the risk of hepatitis flare after NA cessation. These findings support the role of humoral immunity in CHB immunopathogenesis. CLINICAL TRIALS REGISTRATION: The study clinical trial ID is NCT02581033.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hume SJ, Visvanathan K, Cheng K, et al. Anti-HBs Immune Complex Levels: A Novel Marker of Hepatitis Flare Following Nucleos(t)ide Analog Withdrawal in HBeAg-negative Chronic Hepatitis B. J Infect Dis. 2026. PMID: 41239780. doi:10.1093/infdis/jiaf569

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。